Abstract: Objective To investigate the value of the combined detection of pepsinogen(PGⅠ, PGⅡ), gastrin-17(G-17) and neural precursor cell expressed developmentally down-regulated 9(NEDD9) in the diagnosis of gastric cancer. Methods The serum samples of 95 cases of patients with gastric cancer(gastric cancer group) and 140 patients with gastritis(gastritis group) from January 2018 to December 2018 in the People′s Hospital of Zhengzhou were collected, and another 100 healthy subjects in the same period were selected as normal control group. The levels of PGⅠ, PGⅡ, G-17 and NEDD9 were detected by enzyme linked immunosorbent(ELISA). The diagnostic efficiency was evaluated by receiver operating characteristic(ROC) curve analysis and the combined detection of predictors were calculated by logistic regression. Results The expression level differences of PGⅠ, G-17 and NEDD9 between the gastric cancer group and the normal control group were statistically significant(all P<0.05); The PG Ⅱ expression level difference between the gastritis group and the normal control group were statistically significant(P<0.05).The expression levels of G-17 and NEDD9 in early gastric cancer were lower than those in advanced gastric cancer(both P<0.05). The area under the ROC curve(AUC) of PGⅠ, PG Ⅱ, G-17 and NEDD9 in the diagnosis of gastric cancer were 0.664, 0.570, 0.602, 0.749, respectively, and the joint detection of AUC was 0.827, the corresponding sensitivity and specificity were 80.0% and 72.9%, respectively. Conclusion The combined detection of PGⅠ, PGⅡ, G-17 and NEDD9 can improve the diagnosis efficiency of gastric cancer.

Key words: Gastric Cancer, Pepsinogen, Gastrin-17, NEDD9, Diagnosis